How a Specialty Pharmacy Monetized Employees’ Disabilities — Triggering ADA, GINA, FCA, HIPAA, and Anti‑Kickback Liability
Most HR violations start with a bad decision. A manager who didn't document. A policy that wasn't followed. A complaint that got buried. Those are fixable. Those are training problems. What happened at this specialty pharmacy was different. This was not a failure of execution. It was a failure of structure — a company that allegedly redesigned its entire workforce strategy around a single premise: that employees with hemophilia were more valuable for their prescriptions than for their work.
The result was a cascade of multi-statute liability exposure touching the ADA, GINA, Title VII, the Anti-Kickback Statute, and the False Claims Act. And at the center of every violation was the same root cause: HR had been subordinated to revenue, and nobody with the authority or the training to stop it ever did.
For business owners, executives, and HR leaders — especially in healthcare, biotech, pharma, or any industry where your product intersects with your workforce — this case is not a cautionary tale from a different world. It is a blueprint for how quickly an organization collapses when the firewall between HR and revenue breaks down. This is what that collapse looks like. And this is what it takes to make sure it never happens inside your company.
The Sales Strategy: Target Employees With Hemophilia to Monetize Their Treatment Regimens
Let's call this what it was: a sales strategy, not a hiring strategy. According to the EEOC’s allegations, the employer didn't bring people with hemophilia into the organization because of their talent, experience, or ability to contribute. They brought them in because their medical condition — or their children's medical condition — represented high-value, high-frequency, high-reimbursement prescription revenue for the employer.
Critically, the selection of these candidates was itself driven by their diagnosis. Employees weren't screened for qualifications and then found to have hemophilia. They were identified because of their or their dependent’s hemophilia — and hired precisely because that diagnosis made them susceptible to the pressure campaign that would follow. The employment offer was never the end goal. It was the mechanism. Once inside the organization, employees could be incentivized, pressured, or coerced into switching treatment regimens, increasing infusion frequency, and filling prescriptions through the company's own pharmacy — all of which generated enormous revenue for the employer.
The company allegedly collected detailed medical and genetic information during the hiring process — dosage, infusion frequency, inhibitor status, treatment regimen — none of which had any legitimate business purpose. They weren't gathering this information to accommodate employees, ensure safety, or evaluate job fit. They were gathering it to forecast revenue.
The interview wasn't about whether the candidate could do the job. It was about whether the candidate's hemophilia could fund the business model. Employees weren't hired to perform work. They were hired to generate insurance-reimbursed income. That’s not HR. That’s not recruiting. That’s not healthcare. That’s a sales pipeline built on employees’ vulnerabilities and a blatant violation of GINA, that protects everyone regardless of their own or family’s medical history.
The Job Titles Were Real. The Work Was Optional. The Prescriptions Were Mandatory.
Once hired, employees with hemophilia were allegedly placed into roles that looked legitimate on paper — Director of Programs, Regional Sales Representative, Patient Advocate — but were not assigned meaningful work. In at least one case, an employee was told she didn't need to work at all. She only needed to submit time sheets so payroll could run. Her value wasn't her labor. It was her children's medication volume.
When a company hires people for their medical conditions rather than their skills, and then does not require them to do any work, employment becomes a façade — a thin layer of legitimacy covering a fundamentally exploitative revenue model that would plummet any workforce’s morale.
The Pressure Campaign: Prescription Steering, Medication Switching, and Termination Threats in Violation of ADA and GINA
The allegations describe a relentless, systemic pressure campaign. Employees with hemophilia were pushed to switch their medication to brands that were more profitable for the company. They were pressured to move from as-needed treatment to preventative regimens requiring more frequent, more expensive infusions. These treatment regimens could be as expensive as $100,000+ per month per person. They were reprimanded if they didn't order their medication through the company, told their jobs depended on switching to the company's preferred brand, and terminated under the guise of "reorganization" when they refused.
This wasn't subtle. It wasn't accidental. And it created a workplace where deeply personal medical decisions were treated as performance metrics.
Let’s Be Honest: This Wasn’t Just Unethical — It Looked Like a Coordinated Insurance‑Fraud Scheme Built on Employees’ Medical Conditions
While the EEOC focused on the ADA and GINA violations, there was far greater risk lying just under the surface. When you step back and look at the structure of what the company allegedly did, the insurance-fraud indicators are impossible to miss. Hiring people because their hemophilia prescriptions generated massive monthly reimbursements. Collecting detailed medical and genetic information during hiring with no legitimate business purpose. Pressuring employees to switch to more profitable drugs. Tying continued employment to filling prescriptions through the company's own pharmacy.
That's not just discrimination. That's the kind of conduct that triggers insurance-fraud investigations in specialty pharmacy cases.
If any of these employees were covered by Medicare, Medicaid, TRICARE, or VA benefits, the pressure to switch medications or use the employer's pharmacy could also implicate the federal Anti-Kickback Statute — which prohibits offering or receiving anything of value to influence where federally reimbursed healthcare services are obtained. If even one employee's treatment was federally funded, this wasn't just an ADA/GINA disaster. It was potentially a criminal one.
Additionally, the conduct alleged also sits squarely inside the kind of behavior that triggers HIPAA investigations. Specialty pharmacies are HIPAA‑covered entities, and using employees’ prescription data for hiring, revenue forecasting, or medication‑switch pressure is not a legitimate treatment or operations purpose. Under HIPAA, those activities resemble unconsented marketing — and sharing PHI with managers for sales strategy is a confidentiality breach. In other words, the conduct wasn’t just an ADA and GINA failure. It looked like a HIPAA failure too. Fines for this type of conduct can reach more than $68K per violation!
The Qui Tam Exposure: Why This Fact Pattern Could Also Trigger False Claims Act Liability
There is another layer of risk in this case — one that sits outside the EEOC's jurisdiction but squarely within the world of federal fraud enforcement.
Under the False Claims Act, private individuals — including employees — can file qui tam lawsuits on behalf of the United States when a company knowingly causes false claims to be submitted to a federal healthcare program. The Factor One allegations describe exactly the kind of conduct that supports FCA liability: pressuring employees to switch to more expensive drugs, pushing medically unnecessary preventative infusion regimens, coercing employees to fill prescriptions through the employer, tying employment and pay to prescription volume, sharing genetic and prescription information among managers, and hiring employees for the express purpose of generating unneeded prescriptions for costly treatments.
If any of those prescriptions were billed to a federal program, the claims may have been tainted by illegal inducements — which automatically makes them false claims under federal law. And because the Anti-Kickback Statute treats employment, salary, job security, and no-work positions as "things of value," any prescription filled under pressure could trigger FCA liability.
Employees with hemophilia had firsthand knowledge of the pressure campaigns. Employees without hemophilia had insider visibility into the scheme. Both groups had standing to file as whistleblowers. This wasn't just an employment-law disaster. It had the potential to destroy the company and relocate the C-Suite to Club-Fed.
The Two-Tier Workforce: Why Employees Without Hemophilia Also Have Claims under GINA and other Labor Laws
This employer didn't just exploit employees with hemophilia — it created a two-tier workforce built entirely on illegally obtained medical and genetic information. Employees with hemophilia were allegedly recruited for their prescription value, given job titles with little or no actual work, paid regardless of performance, and protected from termination as long as their prescriptions flowed through the company. Employees without hemophilia were expected to perform actual work, meet performance standards, justify their paychecks, and carry the operational load of the business.
The critical compliance point is this: the only reason non-hemophilia employees were held to different standards is because the employer had already violated GINA by collecting medical and genetic information and sorting its workforce based on it. The company allegedly asked candidates about their hemophilia, their children's hemophilia, dosage, infusion frequency, inhibitor status, and treatment regimen — none of which had any legitimate business purpose. That illegal information-gathering became the sorting mechanism that determined who would be treated as a revenue generator and who would be treated as an actual worker. GINA protects all employees’ genetic information, so those who were forced to perform work because they didn’t have hemophilia had standing to sue the employer for disparate treatment.
It didn't stop there. Management allegedly shared employees' genetic information and prescription data with one another as a sales strategy — a practice explicitly prohibited under both ADA confidentiality rules and GINA's genetic-information privacy requirements. In a compliant organization, medical information is locked down, need-to-know, and handled with clinical-grade confidentiality. But this employer treated that information as a sales tool — and circulated it among managers to track which employees were generating the most prescription revenue and which ones needed to be pressured to switch medications.
Once the company created that structure, everything else followed: employees with hemophilia were paid for their prescriptions; employees without hemophilia were paid for their labor; one group was protected and the other was expendable.
That is not just discrimination against people with hemophilia. It is discrimination against everyone else — because the entire employment system was built on an unlawful medical and genetic sorting process. Employees without hemophilia may have claims under disparate treatment, hostile work environment, the Equal Pay Act, wage-and-hour inequity, whistleblower retaliation, wrongful termination, and public-policy retaliation — because the harm they suffered flowed directly from the employer's illegal acquisition, sharing, and use of genetic and medical information, or because they perceived other discriminatory conduct which the employer could not rebut with a legitimate reason.
This is the kind of structural discrimination that doesn't just violate one law. It violates several simultaneously.
The Settlement: What the EEOC Did — and What It Signals
The EEOC ultimately settled this case for $515,000 — and the monetary figure, while significant, was not the most consequential part of the resolution. The agency also entered into a consent decree containing a provision that rarely appears in EEOC settlements: a permanent bar prohibiting the company from ever employing the CEO who ran the organization while these violations were occurring. That is not a standard remedial measure. It is a structural sanction — one that reflects the EEOC's assessment that the conduct was not the result of poor training, inadequate policy, or a failure of oversight. It was the result of leadership. The agency's message was direct: the person who designed and operated this model cannot be permitted to return to the organization, even in a future capacity, because the risk of recurrence is not hypothetical. For business owners and executives, the consent decree is the part of this case that demands the most attention. Monetary settlements end. Consent decrees follow the company. And when the EEOC determines that the threat to employees is so fundamental that it must be written into a court-enforceable order — including a permanent prohibition on rehiring the executive responsible — it is no longer a compliance story. It is a governance story. The question every leader should be asking is not whether their company would settle. It is whether their HR function is independent enough, experienced enough, and structurally protected enough to stop this kind of conduct before it reaches the EEOC at all.
What Employers Should Do Now
This case shows how easily an organization can drift into unlawful territory when recruiting, screening, and HR workflows are not designed to protect medical and genetic information. The fixes are practical, straightforward, and applicable to any employer in healthcare, biotech, pharmacy, or any industry where employee medical conditions might intersect with business operations.
1. Review your recruiting channels — and why they’re being used
Start by examining where your candidates are coming from and whether those sources unintentionally (or intentionally) cluster around certain medical conditions.
Questions to ask:
Why were these channels selected?
Do they overlap with product‑utilization goals?
Are they producing candidates with similar diagnoses or treatment needs?
Did someone choose these channels because they believed certain applicants would be “a good fit” for the business model?
If your recruiting pipeline consistently produces medically vulnerable candidates, that ican be a structural risk — not a coincidence.
2. Review your application for prohibited medical or genetic inquiries (including veiled inquiries).
Your application should never solicit information that is likely to solicit disclosure of a candidate’s medical condition, disability, or dependents’ disabilities or medical challenges. Sometimes HR gets frustrated with workforce challenges like tardiness, or calling out after the employee’s scheduled shift time. However, asking a question like “can you commit to showing up on time every day?” may result in a disclosure about sleep apnea, bipolar disorder, or a range of other medical conditions or disabilities. It’s sufficient to post the shift hours in the ad or to tell a candidate the work schedule.
3. Train recruiters so they don’t start conversations that solicit medical or disability information
Recruiters often unintentionally prompt medical disclosures because they think they’re highlighting a benefit. They should be trained to avoid:
mentioning healthcare discounts
describing “treatment convenience”
referencing specialty‑pharmacy access
implying that candidates who use certain medications would love working there
discussing any benefit tied to a specific medical condition
These comments seem harmless, but they routinely cause applicants to disclose diagnoses, treatment plans, or disability status — which is prohibited under ADA and GINA at the pre‑offer stage.
Recruiters must understand that their job is to avoid conversations likely to elicit medical information, not accidentally start them.
4. Review who is involved in hiring — and remove anyone who shouldn’t be
Audit your hiring process:
Who screens candidates?
Who conducts interviews?
Who participates in hiring discussions?
Who has access to candidate information?
Sales, product, or revenue‑generating teams should not be involved in hiring unless the role directly reports to them. Their involvement increases the risk that medical information will be used — or sought — for business reasons.
5. Rebuild the firewall between HR and revenue
This is structural, not symbolic.
HR should not report into sales or operations.
HR performance metrics should not include revenue or product‑utilization goals.
HR must have authority to stop workflows that touch medical information or other labor law violations.
When HR is structurally tied to revenue, compliance becomes optional — and liability becomes predictable. CHRO can lead your HR complianceinitatives through our Outsourced CHROprogram.
6. Lock down medical and genetic information with strict access controls
Medical information must be:
stored in HR‑only systems
accessible only to HR
used only for accommodation or safety
never circulated to managers or revenue teams
If medical information is being used for forecasting, staffing, or performance management, the organization is already out of compliance. CHRO can help companies ensure this confidentiality through its ADA Compliance Outsourcing and FMLA Administration.
7. Train managers on ADA, GINA, HIPAA, and Anti‑Kickback boundaries
Managers need practical, operational training — not generic “don’t ask medical questions” slides.
They must understand:
why medical inquiries are prohibited
why genetic information cannot be collected
why PHI cannot be used for business strategy
why pressuring medication switching is unlawful
why documentation cannot cure illegal conduct
Managers are the most common failure point. Train them accordingly. Need assistance on training managers? CHRO can help you with comprehensive manager training that is adapted to your industry and your workforce challenges.
8. Audit incentive structures for medical‑condition dependencies
Review all incentives for:
prescription volume
product utilization
medication switching
“program participation” tied to treatment decisions
If incentives reward conduct touching medical conditions in a way that could trigger anti-kickback violations or pose risk under other laws, they need to be dismantled immediately.
Bottom Line
Employers in regulated industries succeed when they treat compliance as part of organizational architecture — not paperwork. Medical conditions are not revenue streams. Genetic information is not a business asset. And once medical information enters recruiting, screening, or HR decision‑making, the organization is no longer managing risk. It is creating it.
CHRO provides companies with outsourced HR support including ADA & FMLA Administration, Outsourced Employee Relations Support, and our comprehensive package designed to support and develop inexperienced HR personnel, the Outsourced CHRO program. Contact us to schedule a confidential consultation.
Click here to read the Complaint the EEOC filed in Colorado District Court in this case
People Also Ask
Can employers ask about an employee's medical or genetic information during hiring?
No. Under the ADA and GINA, employers cannot request medical or genetic information during the hiring process unless it is job-related and consistent with business necessity — a standard that was not met in the Factor One allegations, where the information was collected solely to forecast prescription revenue.
Is it illegal for employers to pressure employees to use a specific medication or pharmacy?
Yes. Pressuring employees to switch medications or fill prescriptions through the employer's pharmacy can violate the ADA, GINA, and the Anti-Kickback Statute, and may trigger False Claims Act liability if any of the prescriptions involved federal healthcare reimbursement.
Can employees file a qui tam lawsuit if their employer engages in prescription-based fraud?
Yes. Employees with firsthand knowledge of prescription steering, medically unnecessary treatment pressure, or kickback-tainted claims may file a qui tam action under the False Claims Act on behalf of the United States — and may be entitled to a share of any government recovery.
Can non-disabled employees bring claims if disabled employees are favored for unlawful reasons?
Yes. Non-disabled employees may have claims for disparate treatment, hostile work environment, wage-and-hour inequity, whistleblower retaliation, and wrongful termination when the preferential treatment of another group flows directly from the employer's illegal acquisition and use of genetic information.
If your organization operates in healthcare, biotech, pharmacy, or any industry where employee medical conditions intersect with revenue, you cannot afford compliance drift. CHRO helps employers build ADA‑ and GINA‑aligned systems, reinforce HR governance, and eliminate structural risk before it becomes litigation.
Contact Concierge Human Resources Officer, LLC to strengthen your HR infrastructure and protect your organization from ADA, GINA, and other non-compliance exposure.
